An Open-Label Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of RO7034067 in Adult and Pediatric Patients With Spinal Muscular Atrophy
Phase of Trial: Phase II
Latest Information Update: 04 May 2018
At a glance
- Drugs Risdiplam (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Acronyms Jewelfish
- Sponsors Roche
- 27 Apr 2018 Planned primary completion date changed from 5 Apr 2019 to 1 Dec 2020.
- 23 Apr 2018 Planned End Date changed from 5 Apr 2019 to 1 Dec 2020.
- 16 Apr 2018 According to the Genentech media release, data from this study will be presented at the 70th American Academy of Neurology (AAN) Annual Meeting 2018.